<DOC>
	<DOC>NCT00909636</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability and pharmacokinetics of escalating multiple doses of the ABT-333 tablet formulation in healthy adult subjects.</brief_summary>
	<brief_title>A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet</brief_title>
	<detailed_description />
	<criteria>overall healthy subjects between the ages of 18 to 55 years old; if female, subject must be either postmenopausal for at least 2 years or surgically sterile; females must have negative results for pregnancy tests performed; if male, subject must be surgically sterile or practicing at least 1 of the following methods of birth control: partner(s) using IUD, partner(s) using oral, injected or implanted methods of hormonal contraceptives, subject and/or partner(s) using doublebarrier method; Body Mass Index is 18 to 29, inclusive history of significant sensitivity to any drug; positive test for HAV IgM, HBsAg, HCV Ab or HIV Ab; history of gastrointestinal issues or procedures; history of seizures, diabetes or cancer (except basal cell carcinoma); clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder; use of tobacco or nicotinecontaining products with the 6month period prior to study drug administration; donation or loss of 550 mL or more blood volume or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration; clinically significant abnormal screening laboratory analyses and ECGs: ALT &gt; ULN, AST &gt; ULN, ECG with QTcF&gt;450 msec in females and &gt;430 msec in males, or ECG with 2nd or 3rd degree atrioventricular block; current enrollment in another clinical study; previous enrollment in this study; recent (6month) history of drug/alcohol abuse that could preclude adherence to the protocol; pregnant or breastfeeding female; requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis or use within the 2week period prior to the first dose of study drug administration or within 10 halflives of the respective medication; use of known inhibitors or inducers of cytochrome P450 3A or cytochrome P450 2C8 within 1 month prior to study drug administration; positive screen for drugs of abuse, alcohol, or cotinine; receipt of any drug by injection within 30 days prior to study drug administration; receipt of any investigational product within a time period equal to 10 halflives of the product or a minimum of 6 weeks prior to study drug administration; consumption of alcohol within 48 hours prior to study drug administration; consumption of grapefruit, grapefruit products, star fruit, or star fruit products within the 72hour period prior to study drug administration; consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive ABT333; history of cardiac disease, including family history of longQT syndrome or unexplained sudden death.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>multiple ascending doses (MAD)</keyword>
</DOC>